Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy

N Turner, S Hamidi, R Ouni, R Rico… - Frontiers in …, 2024 - frontiersin.org
Although most follicular-derived thyroid cancers are well differentiated and have an overall
excellent prognosis following treatment with surgery and radioiodine, management of …

[HTML][HTML] Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report

L Zhu, S Ma, B Xia - Frontiers in Oncology, 2022 - frontiersin.org
Little is known about the efficacy of alectinib for papillary thyroid cancer with STRN-ALK
fusion. A 64-year-old female presented with metastatic papillary thyroid cancer, widespread …

[HTML][HTML] Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022

J Wu, Y Yang, J Yu, L Qiao, W Zuo, B Zhang - Orphanet Journal of Rare …, 2023 - Springer
Background Compassionate use is a system that provides patients with expedited access to
drugs which has not yet been approved, but currently in clinical trials. The investigational …

[HTML][HTML] Kinase inhibitors in thyroid cancers

V Sukrithan, P Jain, MH Shah, B Konda - Endocrine Oncology, 2023 - eo.bioscientifica.com
Objective The treatment landscape for thyroid cancers has changed rapidly with the
availability of kinase inhibitors against VEGFR, BRAF, MEK, NTRK, and RET. We provide an …

Molecular testing in thyroid cancer

JM Skaugen, YE Nikiforov - Diagnostic Molecular Pathology, 2024 - Elsevier
Thyroid cancer is the most common endocrine malignancy. Thyroid cancer typically
manifests as a thyroid nodule, although the majority of thyroid nodules are benign. Several …

Issues with the targeted therapy of non‑small cell lung cancer with thyroid metastases: A case report

E Bayram, T Toyran, B Güney… - Medicine …, 2023 - spandidos-publications.com
Lung cancer is a common malignancy that has usually already metastasized at the time of
diagnosis; however, thyroid metastases are extremely rare. Echinoderm microtubule …

Molekular zielgerichtete Therapien beim radiojodrefraktären differenzierten Schilddrüsenkarzinom–Update 2022

VF Koehler, CB Westphalen, J Nagarajah, M Zacherl… - Die Onkologie, 2022 - Springer
Zusammenfassung Hintergrund Der individualisierte Einsatz der systemischen molekular
gezielten Therapien erfolgt beim radiojodrefraktären differenzierten Schilddrüsenkarzinom …